Drug Profile
STI 4398
Alternative Names: COVIDTRAP™ protein; STI-4398Latest Information Update: 10 Jun 2020
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer Sorrento Therapeutics; University of Texas Medical Branch
- Class Antivirals; Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action ACE modulators; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 05 Jun 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route) before June 2020 (Sorrento Therapeutics pipeline, June 2020)
- 05 Jun 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route) (Sorrento Therapeutics pipeline, June 2020)
- 05 Jun 2020 Sorrento Therapeutics plans a clinical trial for COVID-2019 infections (Prevention) in USA